CCS
PTCT icon

Crosspoint Capital Strategies’s PTC Therapeutics PTCT Stock Holding History

Crosspoint Capital Strategies’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-94
Closed -$6K – 644
2015
Q1 		$6K Buy
+94
New +$5.74K ﹤0.01% 431

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return

Crosspoint Capital Strategies's PTCT Position: Q2 2015 in Review

Crosspoint Capital Strategies sold out of PTC Therapeutics (PTCT) in Q2 2015, closing a stake of 94 shares — an estimated $6K sold.

Crosspoint Capital Strategies first reported a position in PTCT in Q1 2015 and held it in 1 quarter. The position peaked at $6K in Q1 2015. 155 funds tracked by Wall St. Rank hold PTCT as of Q2 2015.

  • Crosspoint Capital Strategies reported no remaining PTC Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 94 PTC Therapeutics shares in Q2 2015, an estimated $6K.
  • Crosspoint Capital Strategies first reported a position in PTC Therapeutics in Q1 2015 and held it in 1 quarter.
  • Crosspoint Capital Strategies's PTC Therapeutics position peaked at $6K in Q1 2015.
  • 155 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2015.

Based on Crosspoint Capital Strategies's 13F filing for Q2 2015, filed 24 Aug 2015.